LGR5 in breast cancer and ductal carcinoma in situ: a diagnostic and prognostic biomarker and a therapeutic target

Table 2 Correlation between LGR5 expression and clinicopathologic features in DCIS

Variable	Patients N (%)	LGR5 intensity				R	P value
		0	1	2	3
All	119 (100)	38	38	30	13
Age
< 50	38 (31.9)	13	11	11	3	0.027	0.77
≥ 50	81 (68.1)	25	27	19	10
Tumor size
≤ 20 mm	73 (76)	29	24	14	6	0.26	0.01
> 20 mm	23 (24)	3	8	9	3
Proliferation
< 10%	60 (57.1)	19	15	16	10	−0.046	0.63
≥ 10%	45 (42.9)	10	20	13	2
Nuclear grade
1	11 (9.2)	6	3	1	1	0.081	0.38
2	46 (38.7)	14	14	13	5
3	62 (52.1)	18	21	16	7
ER
≤ 10%	33 (29.5)	8	9	11	5	−0.163	0.085
> 10%	79 (70.5)	28	27	17	7
PR
≤ 10%	52 (46.8)	15	15	16	6	−0.086	0.37
> 10%	59 (53.2)	20	20	13	6

Abbreviations: LGR5 Leucine-rich repeat-containing G-protein coupled receptor 5, R correlation coefficient, ER estrogen receptor, PR progesterone receptor; Proliferation by IH or S-phase Spearman correlation, two-tailed P -value. Bold indicates P -value < 0.05

ISSN: 1471-2407